New Startup Haemanthus Aims for Health Optimization
Billy Evans, the partner of former Theranos founder Elizabeth Holmes, is embarking on a new venture with his startup titled Haemanthus. This company is focused on innovative approaches to “human health optimization” through advanced blood testing technologies, as reported by The New York Times.
About Haemanthus
Reports indicate that Evans has garnered interest from potential investors, with two of them having been pitched on Haemanthus’ offerings. Inside the marketing materials reviewed by The Times, the startup claims to have created a machine that utilizes laser technology to analyze blood, saliva, and urine samples for the detection of cancers and infections.
Target Market and Funding Goals
Haemanthus plans to first enter the pet health market before expanding its services to humans. The startup is seeking to raise over $50 million to fund its initiatives.
Echoes of Theranos
This approach has drawn comparisons to Theranos, which once promised similar capabilities by performing multiple medical tests on minimal blood samples. Following her convictions on fraud charges, Elizabeth Holmes was sentenced in 2022 to 11 years in prison. Despite her legal troubles, Holmes has expressed her ongoing commitment to making affordable healthcare accessible.
Investors’ Perspectives
Notable investor Jim Breyer, who had early involvement with Facebook, disclosed to The Times that he and his team were invited to invest in Haemanthus but ultimately decided against it. Breyer cited concerns similar to those that prompted his team to pass on opportunities with Theranos.
Conclusion
As Haemanthus seeks to carve its niche within the health technology landscape, observers remain cautious, given the history associated with its founder’s previous enterprise. The trajectory of this new venture will likely be closely monitored by both the medical community and potential investors.